These observations are in line with our previous findings concerning no differential effect of adjuvant chemotherapy on distant disease-free and breast cancer-specific survival in CHEK2 1100delC mutation carriers versus non-CHEK2 patients with early BC (Kriege et al. 2014). The gene discussed is CHEK2; the disease is breast carcinoma.